Sorin Group Wins Approval to Market Heart-Lung Machine in Japan
Posted on: Tuesday, 22 April 2008, 09:01 CDT
The Sorin Group has received the Japanese Pharmaceutical and Medical Devices Agency's approval to market its Stockert S5 Heart-Lung Machine in Japan.
The Stockert S5 is the fifth-generation of heart-lung machines and the successor to Sorin Group's SIII perfusion system. The company claims that the S5 technology sets new standards for safety, functionality and quality and will help hospitals achieve better patient outcome.
Michel Darnaud, president, Cardiopulmonary Business Unit and Intercontinental, Sorin Group, said: "With the launch of the new S5 in Japan, I am confident the Sorin Group will gain market leadership in heart-lung machines in this key country and further consolidate its leading worldwide market share."
Source: Datamonitor
Related Articles
- Umbilical Cord Blood Stem Cell Transplant May Help Lung, Heart Disorders
- Reportlinker Adds The Market for Heart Benefit Foods (3rd Edition)
- This Essential Platinum-Group Metals Market Review is Now Available
- Sorin Group Receives Approval to Market S5 Heart-Lung Machine in Japan and Announces Landmark Shipment of 7000th Heart-Lung Machine
- Alaska Airlines Names New MD of Leisure and Group Travel Marketing
- Alaska Airlines Names Brad Walker Managing Director of Leisure, Group Travel Marketing
- OLB Group Announces Marketing and Distribution of Flowers and Gift Baskets at Up to 60% Discount to Retail
- Who's Covering America's Group Health Market? Update From Mark Farrah Associates (MFA)
- Painkillers Should All Stay on Market, Despite Heart Risks: FDA Panel
- Celebrex Should Stay on Market, Despite Heart Risks: FDA Panel
 |
 |
User Comments (0)
RSS Feeds